Loading news article.

Newsfiscal.ai

Acrivon Therapeutics Advances ACR-7280 as Next Development Candidate

Oct 20, 2026, 09:03 ET · Published

Article summary

Acrivon Therapeutics has announced the advancement of ACR-7280, a potential first-in-class, oral CDK11 inhibitor, as its next development candidate derived from its proprietary AP3 platform.

An excerpt from the original article.

Related companies

Acrivon Therapeutics, Inc. Common StockACRVView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…